Open AccessSystemic therapy of hepatocellular carcinoma: reality and prospects
Author(s) -
В. В. Бредер,
М. В. Натрусова,
И. А. Джанян
Publication year - 2020
Publication title -
annaly hirurgičeskoj gepatologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 1
eISSN - 2408-9524
pISSN - 1995-5464
DOI - 10.16931/1995-5464.2020227-38
Subject(s) - medicine , hepatocellular carcinoma , immunotherapy , liver transplantation , cirrhosis , oncology , monoclonal antibody , systemic therapy , combination therapy , clinical trial , carcinoma , cancer , transplantation , immunology , antibody , breast cancer
This article discusses the results of clinical trials and the perspectives for perioperative systemic therapy for liver cancer, as well as the effectiveness of combination with locoregional methods. Special attention is paid to first and second line hepatocellular carcinoma therapy, as already approved in the Russian Federation (multikinase inhibitors, monoclonal antibodies to the vascular endothelial growth factor receptor, checkpoint inhibitors), as well as ongoing clinical trials. Promising combinations of immunotherapy with multikinase and (or) angiogenic inhibitors, potential predictors of the effectiveness of immunotherapy for hepatocellular carcinoma, as well as the features of therapy after orthotopic liver transplantation and against the background of non-compensated liver cirrhosis, are considered.